Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Treating Advanced Prostate Cancer: Increasing Complexity

New E-Learning module by Prof De Bono, by Dr Beije and by Dr Longoria is now available. Watch the presentation and take the CME test today!

Background image on hero resources block

Access to this content is restricted

Login with your ESMO Account

Learning objectives

  1. To provide an update on advances in therapeutic strategies for patients with advanced prostate cancer
  2. To provide insights on inter-patient heterogeneity and implications on management
  3. To provide insights on intra-patient heterogeneity and implications on resistance

Description

In this E-Learning module, the authors elaborate on the rapidly changing treatment landscape in advanced prostate cancer with molecular stratification as standard of care, multiple lines of treatment being available, and additionally many novel anticancer therapeutic strategies becoming evaluated. The authors explain inter- and intra-patient heterogeneity and their implications on management.

The authors start the module by explaining changes in prostate cancer diagnosis and staging. They underline that improved imaging is leading to stage migration, consequently decreasing the prevalence of M0 disease with rising PSA.

The authors explain that advanced prostate cancer comprises clinically important disease subsets and these molecular subsets need to be recognised to optimise care. Molecular characterisation identifies both, inter- and intra-patient heterogeneity, and both can have an impact on disease behaviour, survival outcomes, and treatment sensitivity.

The authors state that, treatments for advanced prostate cancer include LHRH analogues or surgical castration, next-generation androgen receptor signalling inhibitors (abiraterone, enzalutamide, apalutamide, darolutamide), lutetium PSMA, PARP inhibitors, immune checkpoint inhibition, docetaxel, cabazitaxel. Local disease control remains important, even in locally advanced disease, and can improve survival in patients with low-volume metastatic disease. They also elaborate on new therapeutic strategies.

The authors underline that, optimal drug sequencing is not adequately defined, but as with other diseases, it is likely that precise positioning is less important than the patients receiving all the key drug classes at some point in their course of disease. They also underline that men with prostate cancer are living longer and better than ever before.

This E-Learning module provides an excellent overview of recent advances in the management of patients with advanced prostate cancer.

Declaration of interest

Johann de Bono has reported:
Financial Interests:
Advisory Board, Personal: Amgen, Astellas, Astra Zeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi, Eisai, Genentech Roche, Genmab, GlaxoSmithKline, Harpoon, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals, Menarini Silicon Biosystems, ImCheck Therapeutics, Crescendo.
Research Grant, Institutional: Astellas, Astra Zeneca, Bayer, Cellcentric, Daiichi, Genentech Roche, Genmab, GlaxoSmithKline, Harpoon, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Sanofi Aventis, Sierra Oncology, Taiho, Vertex Pharmaceuticals, Crescendo Biologics, Menarini Silicon Biosystems.
Non-Financial Interests:
Principal Investigator: Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi, Eisai, Genentech Roche, Genmab, GlaxoSmithKline, Harpoon, Janssen, Menarini Silicon Biosystems, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals, Crescendo, ImCheck Therapeutics.
Product Samples, Institutional: Daiichi, Bayer, Merck Serono, AstraZeneca, Harpoon, Pfizer, Sierra Oncology, Genentech/Roche, Sanofi Aventis, GlaxoSmithKline.

Nick Beije has no interests to declare.

Ossian Longoria has no interests to declare.

Last update: 08 Aug 2023

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.